Lighthouse Investment Partners LLC Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Lighthouse Investment Partners LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 19,000 shares of the medical equipment provider's stock, valued at approximately $2,007,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $473,000. KLCM Advisors Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $7,825,000. Van ECK Associates Corp raised its position in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Lmcg Investments LLC lifted its holdings in Zimmer Biomet by 20.4% during the 4th quarter. Lmcg Investments LLC now owns 55,949 shares of the medical equipment provider's stock worth $5,910,000 after buying an additional 9,484 shares in the last quarter. Finally, MFG Wealth Management Inc. bought a new position in Zimmer Biomet in the 4th quarter valued at $1,506,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZBH. Stifel Nicolaus set a $115.00 target price on Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Morgan Stanley cut their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Robert W. Baird cut their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Raymond James reduced their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $113.45.

Zimmer Biomet Stock Down 1.7%

Shares of NYSE:ZBH traded down $1.61 during trading on Monday, hitting $95.34. 646,663 shares of the company's stock traded hands, compared to its average volume of 1,750,410. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $103.41 and a 200-day moving average price of $105.84. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.92 and a 52 week high of $120.13. The company has a market cap of $18.86 billion, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the firm posted $1.94 earnings per share. The business's revenue was up 1.1% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet's dividend payout ratio is 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.